Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology of Resistant Microbial Strains Among Different Groups of People (Healthy, Infected and Exposed to Animals) (ABRESIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03343119
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : October 11, 2018
Sponsor:
Collaborator:
Estonian University of Life Sciences
Information provided by (Responsible Party):
Kaidi Telling, University of Tartu

Brief Summary:
This study investigates carriage rate and risk factors for acquiring multiresistant bacteria (ESBL producing E.coli and K.pneumoniae, carbapenem-resistant and multidrug resistant P.aeruginosa, MRSA and VRE) in hospitalised patients and healthy volunteers.

Condition or disease
ESBL Producing E.Coli ESBL Producing K.Pneumoniae Multidrug Resistant P.Aeruginosa Carbapenem Resistant P.Aeruginosa Methicillin Resistant Staphylococcus Aureus (MRSA) Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)

Layout table for study information
Study Type : Observational
Actual Enrollment : 708 participants
Observational Model: Ecologic or Community
Time Perspective: Other
Official Title: Transfer Routes of Antibiotic Resistance
Actual Study Start Date : March 27, 2012
Actual Primary Completion Date : January 30, 2014
Estimated Study Completion Date : August 2019

Group/Cohort
Hospitalised patients
No intervention
Healthy volunteers
No intervention
Dog owners (healthy volunteers)
No intervention
Veterinarians (healthy volunteers)
No intervention
Pig farmers (healthy volunteers)
No intervention



Primary Outcome Measures :
  1. Colonization rate with multiresistant (MDR) bacteria in hospitalized patients [ Time Frame: March 2012 - March 2014 ]
    To evaluate the impact of hospitalization for carriage and infection rate with MDR bacteria

  2. Colonization rate with multiresistant (MDR) bacteria in healthy humans [ Time Frame: March 2012 - March 2014 ]
    To evaluate the impact of animal exposure for carriage rate with MDR bacteria


Biospecimen Retention:   Samples With DNA
DNA from isolated multiresistant bacteria


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

I group All individuals who have been hospitalised and have been diagnosed carriage or infection with multiresistant bacteria listed above.

II group Children >6 months of age and all adults who have not been hospitalised or received antibacterial treatment in previous 3 months.

Criteria

I group Hospitalised patients Inclusion Criteria

  • MDR bacteria (listed above) isolated from clinical specimen
  • hospitalisation to the Tartu University Hospital or North Estonia Medical Centre or West Tallinn Central Hospital or East-Tallinn Central Hospital or The Hospital of Reconstructive Surgery

II group Healthy volunteers Inclusion Criteria

  • age >6 months
  • have not received any antibacterial treatment in previous 3 months
  • have not been hospitalised in previous 3 months

III group Dog owners Inclusion Criteria

  • age >6 months
  • have not received any antibacterial treatment in previous 3 months
  • have not been hospitalised in previous 3 months
  • owning a dog

IV group veterinarians Inclusion Criteria

  • have not received any antibacterial treatment in previous 3 months
  • have not been hospitaliZed in previous 3 months
  • working as a veterinarian

V group pig farmers Inclusion Criteria

  • have not received any antibacterial treatment in previous 3 months
  • have not been hospitalized in previous 3 months
  • occupation as a pig farmer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03343119


Sponsors and Collaborators
University of Tartu
Estonian University of Life Sciences
Investigators
Layout table for investigator information
Study Director: Tanel Tenson, PhD University of Tartu

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kaidi Telling, MD, University of Tartu
ClinicalTrials.gov Identifier: NCT03343119     History of Changes
Other Study ID Numbers: SLOTI12038T
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Staphylococcal Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Gram-Positive Bacterial Infections
Bacterial Infections